TY - JOUR
T1 - Diagnosis and management of moderate to severe atopic dermatitis in adolescents. A Consensus by the Italian Society of Dermatology and Venereology (SIDemaSt), the Italian association of Hospital Dermatologists and Public Health (aDoI), the Italian association of Hospital and territorial allergists and Immunologists (aaIIto), the Italian Society of allergy, asthma and Clinical Immunology (SIaaIC), the Italian Society of Pediatric allergy and Immunology (SIaIP), the Italian Society of allergological, occupational and environmental Dermatology (SIDaPa), and the Italian Society of Pediatric Dermatology (SIDerP)
AU - raDar group
AU - Calzavara-Pinton, Piergiacomo
AU - Fortina, Anna Belloni
AU - Bonamonte, Domenico
AU - Marseglia, Gian L.
AU - Del Giudice, Michele Miraglia
AU - Musarra, Antonino
AU - Nettis, Eustachio
AU - Neri, Iria
AU - Patruno, Cataldo
AU - Stingeni, Luca
AU - Peris, Ketty
N1 - Publisher Copyright:
© 2020 EDIZIONI MINERVA MEDICA.
PY - 2021/4
Y1 - 2021/4
N2 - Atopic dermatitis (AD) is a chronic inflammatory disease with increasing global incidence, which has a multifactorial pathogenesis and a variable expressivity. Clinical features of AD are different in adults compared to children, but it is well recognized the substantial impact of the disease on patients' quality of life at any age. Indeed, little is known about AD in adolescence, a period of life generally associated with high psychological burden and vulnerability to depression. Guidelines for the management of AD are available for both children and adults but specific guidelines for the diagnosis and treatment of AD in adolescents are lacking. Seven Italian scientific societies of dermatologists, allergists, and pediatric allergists joined in a specific meeting to provide practical guidance for the diagnosis and management of moderate-to-severe adolescent AD suitable for the Italian clinical practice. Through a modified Delphi procedure, consensus was reached by 59 Italian experts in the management of AD on 20 statements covering five areas of interest about adolescent AD, including disease complexity, burden and social impact, diagnosis and defini tion of severity, current treatments, and new biologic therapies. This paper reports recommendations for the diagnosis and management of AD specifically in adolescents, pointing out some peculiar clinical features and focusing on the choice of medications. Dupilumab, the first biologic approved for the treatment of adolescents with AD, represents a useful treatment option due to its efficacy and reassuring safety profile.
AB - Atopic dermatitis (AD) is a chronic inflammatory disease with increasing global incidence, which has a multifactorial pathogenesis and a variable expressivity. Clinical features of AD are different in adults compared to children, but it is well recognized the substantial impact of the disease on patients' quality of life at any age. Indeed, little is known about AD in adolescence, a period of life generally associated with high psychological burden and vulnerability to depression. Guidelines for the management of AD are available for both children and adults but specific guidelines for the diagnosis and treatment of AD in adolescents are lacking. Seven Italian scientific societies of dermatologists, allergists, and pediatric allergists joined in a specific meeting to provide practical guidance for the diagnosis and management of moderate-to-severe adolescent AD suitable for the Italian clinical practice. Through a modified Delphi procedure, consensus was reached by 59 Italian experts in the management of AD on 20 statements covering five areas of interest about adolescent AD, including disease complexity, burden and social impact, diagnosis and defini tion of severity, current treatments, and new biologic therapies. This paper reports recommendations for the diagnosis and management of AD specifically in adolescents, pointing out some peculiar clinical features and focusing on the choice of medications. Dupilumab, the first biologic approved for the treatment of adolescents with AD, represents a useful treatment option due to its efficacy and reassuring safety profile.
KW - Adolescent
KW - Atopic
KW - Dermatitis
KW - Diagnosis
KW - Dupilumab
KW - Therapy
UR - http://www.scopus.com/inward/record.url?scp=85106481149&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85106481149&partnerID=8YFLogxK
U2 - 10.23736/S2784-8671.20.06654-7
DO - 10.23736/S2784-8671.20.06654-7
M3 - Review article
AN - SCOPUS:85106481149
VL - 156
SP - 184
EP - 197
JO - Italian Journal of Dermatology and Venereology
JF - Italian Journal of Dermatology and Venereology
SN - 2784-8671
IS - 2
ER -